Weekly Screener 29 March – 5 April 2021, Week 13
Total Page:16
File Type:pdf, Size:1020Kb
AlsterResearch Weekly Screener Page 1 of 5 Weekly Screener 29 March – 5 April 2021, Week 13 Momentum Target Q1 2021 is ending, and we take a look at the momentum stocks so far this year. Method Calculate total share performance (closing price change plus dividends) from 31.12.2020 until 26.03.2021. Result from AlsterResearch universe: Highest Momentum Name YTD performance EV/EBIT 2022E Sartorius AG 26,0% 33,9x mic AG 25,8% 6,2x Hugo Boss AG 24,8% 13,7x wallstreet:online AG 19,7% 11,4x Formycon AG 19,2% negative MAKING SENSE OF THE NUMBERS: Sartorius AG (AlsterResearch view: HOLD / PT EUR 445 / closing price EUR 439,60 / upside 1%) Sartorius is profiteer of the current pandemic. After an outstanding 2020, order intake for 2021 beat expectations and guidance for 2021 was raised. All this seems reflected in the current rich valuation. mic AG (AlsterResearch view: BUY / PT EUR 5,40 / closing price EUR 3,10 / upside 74%) After a reverse IPO totally transformed the business, the new mic is gradually getting the attention it deserves. Most recently, a value accretive acquisition put the company into the spotlight. Still way to go. Hugo Boss AG (AlsterResearch view: BUY / PT EUR 37 / closing price EUR 33,06 / upside 12%) The pandemic took a big toll on Hugo Boss, with sales slumping 33% and steep losses in 2020. A brightening outlook is providing tailwinds for the stock. But despite playing catch-up, it is still far below pre-Covid levels. wallstreet:online AG (AlsterResearch view: BUY / PT EUR 30 / closing price EUR 19,05 / upside 57%) Darling of the stock market in February, as the stock rallied more than 60%. This was on the back of surging customer growth in brokerage, driven by retail clients in a meme stock frenzy. Stock has since retreated and looks attractive once again. Formycon AG (AlsterResearch view: BUY / PT EUR 80 / closing price EUR 60,20 / upside 33%) The share is benefitting from hopes that a Covid-19 therapeutical drug currently in pre-clinical trials could turn out a blockbuster. Announced cooperations with established players have provided extra credibility. What do you think? Which stock will continue with momentum into Q2? Take our survey and see what other financial professionals think. Result of last week’s survey Which company would you like to work for? Winner: Puma AlsterResearch Weekly Screener Page 2 of 5 Looking beyond our coverage: Momentum in DAX, MDAX and SDAX DAX: Positive Momentum Name YTD performance Volkswagen AG 49,6% Daimler AG 26,8% HeidelbergCement AG 24,1% Siemens AG 19,9% Deutsche Bank AG 17,2% DAX: Negative Momentum Name YTD performance MTU Aero Engines AG -7,4% Deutsche Wohnen SE -7,4% Continental AG -8,6% adidas AG -12,2% Delivery Hero SE -12,6% MDAX: Positive Momentum Name YTD performance Porsche Automobil Holding SE 55,7% ThyssenKrupp AG 34,4% AIXTRON SE 31,2% Prosiebensat 1 Media SE 29,2% Sartorius AG 26,0% MDAX: Negative Momentum Name YTD performance Stroeer SE & Co KGaA -11,5% LEG Immobilien AG -11,7% Fuchs Petrolub SE -11,8% TeamViewer AG -16,9% MorphoSys AG -19,8% SDAX: Positive Momentum Name YTD performance LEONI AG 71,6% SGL Carbon SE 66,3% Eckert&Ziegler Strahlen & Mdzntchnk 57,2% zooplus AG 41,3% ADVA Optical Networking SE 36,8% SDAX: Negative Momentum Name YTD performance Hypoport SE -16,7% ADO Properties SA -17,0% LPKF Laser & Electronics AG -17,7% Patrizia AG -18,1% New Work SE -19,6% AlsterResearch Weekly Screener Page 3 of 5 Conflict of interests Disclosures regarding research publications of SRH AlsterResearch AG pursuant to section 85 of the German Securities Trading Act (WpHG) and distributed in the UK under an EEA branch passport, subject to the FCA requirements on research recommendation disclosures It is essential that any research recommendation is fairly presented and discloses interests of indicates relevant conflicts of interest. Pursuant to section 85 of the German Securities Trading Act (WpHG) a research report has to point out possible conflicts of interest in connection with the analyzed company. Further to this, under the FCA’s rules on research recommendations, any conflicts of interest in connection with the recommendation must be disclosed. A conflict of interest is presumed to exist in particular if SRH AlsterResearch AG (1) or its affiliate(s) (either in its own right or as part of a consortium) within the past twelve months, acquired the financial instruments of the analyzed company, (2) has entered into an agreement on the production of the research report with the analyzed company, (3) or its affiliate(s) has, within the past twelve months, been party to an agreement on the provision of investment banking services with the analyzed company or have received services or a promise of services under the term of such an agreement, (4) or its affiliate(s) holds a) 5% or more of the share capital of the analyzed company, or b) the analyzed company holds 5% or more of the share capital of SRH AlsterResearch AG or its affiliate(s), (5) or its affiliate(s) holds a net long (a) or a net short (b) position of 0.5% of the outstanding share capital of the analyzed company or derivatives thereof, (6) or its affiliate(s) is a market maker or liquidity provider in the financial instruments of the issuer, (7) or the analyst has any other significant financial interests relating to the analyzed company such as, for example, exercising mandates in the interest of the analyzed company or a significant conflict of interest with respect to the issuer, (8) The research report has been made available to the company prior to its publication. Thereafter, only factual changes have been made to the report. Conflicts of interest that existed at the time when this research report was published: Company Disclosure Sartorius AG None mic AG 2 Hugo Boss AG None wallstreet:online AG 2 Formycon AG 2 AlsterResearch Page 4 of 5 Important disclosures 1. General Information/Liabilities This research report has been produced for The decision on the choice of the financial instruments analyzed in this the information purposes of institutional investors only, and is not in any way document was solely made by SRH AlsterResearch AG. The opinions and a personal recommendation, offer or solicitation to buy or sell the financial estimates in this research report are subject to change without notice. It is instruments mentioned herein. The document is confidential and is made within the discretion of SRH AlsterResearch AG whether and when it publishes available by SRH AlsterResearch AG, exclusively to selected recipients [in DE, an update to this research report, but in general updates are created on a GB, FR, CH, US, UK, Scandinavia, and Benelux or, in individual cases, also in regular basis, after 6 months at the latest. A sensitivity analysis is included other countries]. A distribution to private investors in the sense of the German and published in company’s initial studies. Securities Trading Act (WpHG) is excluded. It is not allowed to pass the research report on to persons other than the intended recipient without the 5. Date and time of first publication of the financial analysis permission of SRH AlsterResearch AG. Reproduction of this document, in March 27, 2021 whole or in part, is not permitted without prior permission SRH AlsterResearch AG. All rights reserved. Under no circumstances shall SRH AlsterResearch AG, 6. Risk information any of its employees involved in the preparation, have any liability for possible • Stock exchange investments and investments in companies (shares) errors or incompleteness of the information included in this research report – are always speculative and involve the risk of total loss. neither in relation to indirect or direct nor consequential damages. Liability for • This is particularly true in respect of investments in companies which damages arising either directly or as a consequence of the use of information, are not established and/or small and have no established business or opinions and estimates is also excluded. Past performance of a financial corporate assets. instrument is not necessarily indicative of future performance. • Share prices may fluctuate significantly. This is particularly true for shares with low liquidity (market breadth). Even small orders can have 2. Responsibilities This research report was prepared by the research analyst a significant impact on the share price. named on the front page (the ʺProducerʺ). The Producer is solely responsible • In the case of shares in narrow markets, it may also happen that there for the views and estimates expressed in this report. The report has been is no or very little actual trading there and that published prices are not prepared independently. The content of the research report was not based on actual trading but have only been provided by a stockbroker. influenced by the issuer of the analyzed financial instrument at any time. It • In such markets a shareholder cannot expect to find a buyer for his may be possible that parts of the research report were handed out to the shares at all and/or at reasonable prices. In such narrow markets there issuer for information purposes prior to the publication without any major is a very high possibility of manipulating prices and in such markets amendments there are often considerable price fluctuations. being made thereafter. • An investment in shares with low liquidity and low market capitalization is therefore highly speculative and represents a very high risk. 3. Organizational Requirements SRH AlsterResearch AG took internal • There is no regulated market for unlisted shares and securities and a organizational and regulative precautions to avoid or accordingly disclose sale is not possible or only possible on an individual basis.